JAK1 and rheumatoid arthritis: The effectiveness of the JAK1‐selective inhibitor filgotinib in RA‐ILD remains unknown; however, clinical studies have demonstrated the efficacy of JAKis, particularly TOF and BAR, which are both capable of inhibiting JAK1, in treating RA‐ILD.